We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · September 23, 2021

Durvalumab Plus Tremelimumab for Previously Treated Anti–PD-1/PD-L1–Resistant Stage IV Squamous Cell Lung Cancer

Journal for immunotherapy of cancer


Additional Info

Journal for immunotherapy of cancer
Phase II Study of Durvalumab Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy S1400F, NCT03373760)
J Immunother Cancer 2021 Aug 01;9(8)1-8, NB Leighl, MW Redman, N Rizvi, FR Hirsch, PC Mack, LH Schwartz, JL Wade, WJ Irvin, SC Reddy, J Crawford, JD Bradley, TE Stinchcombe, SS Ramalingam, J Miao, K Minichiello, RS Herbst, VA Papadimitrakopoulou, K Kelly, DR Gandara

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading